Workflow
Harvard Bioscience(HBIO)
icon
Search documents
Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference
Newsfilter· 2025-01-13 22:52
HOLLISTON, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Micro Cap Virtual Conference on January 22nd, 2025, with a presentation time of 10:00 am ET. The presentation will be webcast live and can be accessed through the investor relations section of the Harvard Bioscience website: https://investor.harvardbioscience.com/events- ...
Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference
GlobeNewswire· 2025-01-13 22:52
HOLLISTON, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Micro Cap Virtual Conference on January 22nd, 2025, with a presentation time of 10:00 am ET. The presentation will be webcast live and can be accessed through the investor relations section of the Harvard Bioscience website: https://investor.harvardbioscience.com/events ...
Harvard Bioscience(HBIO) - 2024 Q3 - Earnings Call Transcript
2024-11-09 14:37
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Kathryn Flynn - Corporate Controller James Green - Chairman, President and CEO Jennifer Cote - CFO Conference Call Participants Paul Knight - KeyBanc Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Third Quarter 2024 Harvard Biosciences Inc. Earnings Conference Call. [Operator Instructions] As a reminder, this call may be recorded. I would like to turn the call ...
Harvard Bioscience(HBIO) - 2024 Q3 - Quarterly Report
2024-11-08 21:45
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3306140 (State or other jurisdiction of In ...
Harvard Bioscience(HBIO) - 2024 Q3 - Quarterly Results
2024-11-07 12:02
Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2024 Financial Results HOLLISTON, Mass., November 7, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company") today announced financial results for the third quarter ended September 30, 2024. Jim Green, Chairman and CEO, said, "Our third quarter revenues continued to reflect the effects of the challenging market environment. Our migration to a single US enterprise resource planning system, completed in the third quarter, support ...
Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET
GlobeNewswire News Room· 2024-10-29 21:00
HOLLISTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2024 before the market opens on November 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the audio-only ...
2 Instruments Stocks to Watch From a Challenging Industry
ZACKS· 2024-10-29 19:51
The Zacks Instruments - Scientific industry is suffering from challenging macroeconomic conditions. The continuing war in Ukraine and the conflict in the Middle East increase the risk of rising energy prices and sluggishness in the European economy, which are headwinds. However, increasing healthcare spending, driven by aging demography, and continued innovation in the pharma and life sciences end markets are positives. Higher demand for generic drugs and biosimilars is driving growth for scientific tool an ...
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting
GlobeNewswire News Room· 2024-09-18 11:30
HOLLISTON, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Safety Pharmacology Society (SPS) Annual Meeting being held from September 22-25, 2024, in San Diego. DSI™ Ponemah™ Data Management Platform Provides Integrated Preclinical Solution The Company's Ponemah™ platform, known for its compliance with GLP standards, is a leading tool for managing and analyzing data from a wide range of preclin ...
Harvard Bioscience, Inc. to Participate in the Sidoti Small Cap Virtual Conference
GlobeNewswire News Room· 2024-09-05 20:05
HOLLISTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Small Cap Virtual Conference on September 18th, 2024, with a presentation time of 9:15 am ET. The presentation will be webcast live and can be accessed through the investor relations section of the Harvard Bioscience website: https://investor.harvardbioscience.com/even ...
Harvard Bioscience(HBIO) - 2024 Q2 - Earnings Call Transcript
2024-08-11 11:09
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q2 2024 Earnings Conference Call August 8, 2024 10:00 AM ET Company Participants Kathryn Flynn - Corporate Controller James Green - Chairman, President and CEO Jennifer Cote - CFO Conference Call Participants Paul Knight - KeyBanc Capital Markets Bruce Jackson - The Benchmark Company Christopher Sakai - Singular Research Operator Good day, and thank you for standing by. Welcome to the Q2 2024 Harvard Bioscience, Inc. Earnings Conference Call. At this time, all particip ...